Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DMAA · as of Sep 30, 2025
Ownership Breakdown
37
Institutional Holders
▲ 5 vs Q2
$223.44M
Total Inst. Value
▲ $11.13M vs Q2
33.72M
Shares Outstanding
freeFloat 81.00%
21.76M
13F Shares Held
▲ 934,127 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DMAA largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
KARPUS MANAGEMENT, INC. blank checks | 2.55M | 7.60% | 7.60% | $26.16B | Nov 14, 2025 | ▼ 196.4K |
FIRST TRUST CAPITAL MANAGEMENT L.P. blank checks | 2.24M | 6.69% | 6.69% | $23.03B | Nov 17, 2025 | — held |
POLAR ASSET MANAGEMENT PARTNERS INC. blank checks | 1.90M | 5.67% | 5.67% | $19.51B | Dec 1, 2025 | — held |
GLAZER CAPITAL, LLC blank checks | 1.82M | 5.44% | 5.44% | $18.71B | Nov 13, 2025 | ▼ 158 |
WESTCHESTER CAPITAL MANAGEMENT, LLC blank checks | 1.67M | 4.98% | 4.98% | $17.14B | Nov 14, 2025 | — held |
HUDSON BAY CAPITAL MANAGEMENT LP blank checks | 1.55M | 4.62% | 4.62% | $15.92B | Dec 15, 2025 | ▼ 250.0K |
WOLVERINE ASSET MANAGEMENT LLC blank checks | 1.25M | 3.73% | 3.73% | $12.83B | Oct 28, 2025 | ▲ 227.2K |
MIZUHO SECURITIES USA LLC blank checks | 1.10M | 3.28% | 3.28% | $11.29B | Oct 22, 2025 | ▲ 180.7K |
ARISTEIA CAPITAL LLC blank checks | 881.7K | 2.63% | 2.63% | $9.06B | Nov 14, 2025 | — held |
D. E. SHAW & CO., INC. blank checks | 690.0K | 2.06% | 2.06% | $7.09B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
7
Increased
+952.4K shares10
New Positions
first time holders9
Decreased
−716.8K shares5
Sold Out
fully exitedNet shares change (top 50)
+235.6K
+952.4K / −716.8K
Net new holders
+3
10 new / 5 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DMAA insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
12
Buy transactions
4
Sell transactions
3.00
Buy/Sell ratio
$12M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Drugs Made In America Acquisition LLC 10 percent owner | Feb 18, 2025 | Purchase | 30,000 | — | — | 4.19M | Form 4 ↗ |
Drugs Made In America Acquisition LLC 10 percent owner | Feb 18, 2025 | Purchase | 30,000 | — | — | 430.0K | Form 4 ↗ |
Stockwell Lynn CEO and Exe. Chair of Board | Feb 18, 2025 | Purchase | 30,000 | — | — | 4.19M | Form 4 ↗ |
Stockwell Lynn CEO and Exe. Chair of Board | Feb 18, 2025 | Purchase | 30,000 | — | — | 430.0K | Form 4 ↗ |
Drugs Made In America Acquisition LLC 10 percent owner | Jan 29, 2025 | Purchase | 400,000 | — | — | 10.26M | Form 4 ↗ |
Drugs Made In America Acquisition LLC 10 percent owner | Jan 29, 2025 | J-Other | 400,000 | — | — | 9.86M | Form 4 ↗ |
Drugs Made In America Acquisition LLC 10 percent owner | Jan 29, 2025 | Sale | 5,698,363 | $1.50 | $8.55M | 4.16M | Form 4 ↗ |
Drugs Made In America Acquisition LLC 10 percent owner | Jan 29, 2025 | Purchase | 400,000 | — | — | 400.0K | Form 4 ↗ |
Stockwell Lynn CEO and Executive COB | Jan 29, 2025 | J-Other | 400,000 | — | — | 9.86M | Form 4 ↗ |
Stockwell Lynn CEO and Executive COB | Jan 29, 2025 | Sale | 5,698,363 | $1.50 | $8.55M | 4.16M | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is primarily owned by institutional investors, who hold approximately 64.5% of total shares outstanding. Company insiders own approximately 19.00%, while retail and public investors account for the remaining 16.47%.
The largest institutional shareholder of Drugs Made In America Acquisition Corp. Ordinary Shares is KARPUS MANAGEMENT, INC., holding approximately 2.55 million shares — equal to 7.60% of outstanding shares — as of September 30, 2025.
A total of 37 institutional investors currently hold DMAA stock, with a combined institutional value of approximately $223,437,341 as of the most recent 13F filing period.
Frequently asked questions
DMAA ownershipDrugs Made In America Acquisition Corp. Ordinary Shares (DMAA) is primarily owned by institutional investors, who hold approximately 64.5% of shares. The largest shareholder is KARPUS MANAGEMENT, INC. with a 7.60% stake. Company insiders hold 19.00%. Data sourced from SEC Form 13F as of September 30, 2025.